Astraveus, a Paris, France-based developer of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, received a €10.4M grant from the French government.
This non-dilutive funding closely follows the #FrenchTech2030 accreditation led by the Secrétariat Général Pour l’Investissement (“SGPI)”, building upon the ongoing support received from the French and European innovation ecosystem, and the recent closure of an oversubscribed €16.5M seed financing round.
The company intends to use the funds to advance the development of its Lakhesys ™ platform.
Led by Jérémie Laurent, Founder and CEO, Astraveus is developing the next generation of cell and gene therapy (CGT) manufacturing solutions. Its cell foundries miniaturize and automate cell and gene therapy manufacturing in a modular, end-to-end, microfluidic solution that mimics the elegance of natural systems. The deep process optimization of the platform enables precision and therefore easier replication of optimal manufacturing, delivering better therapies in a more cost- and time-efficient manner, using fewer materials and with reduced environmental impact. Astraveus is supported by AdBio partners, M Ventures, Johnson & Johnson Innovation – JJDC Inc, and Bpifrance Large Venture.
FinSMEs
24/10/2023